A Phase I/II Study of CP-4055 in Patients With Platinum Resistant Ovarian Cancer

Summary

This is non randomised, open label, dose finding, efficacy and safety study, enrolling patients with advanced (stage III and IV) ovarian cancer It will be conducted in two successive phases. Phase II has a two-step design

Timeline

Start

2008-04

Primary completion

2009-11

Completion

2010-04

Drugs

Indications